Merrimack Names CFO
This article was originally published in Scrip
Executive Summary
Merrimack Pharmaceuticals, Inc. has named Dr Yasir Al-Wakeel chief financial officer and head of corporate development – effective from Aug. 11, 2015. Al-Wakeel will serve a key role in continuing to build Merrimack into a fully integrated cancer company based on a systems engineering approach, the company noted. Merrimack currently has a pipeline of oncology candidates led by MM-398 (irinotecan liposome injection), which is currently under FDA review for approval in post-gemcitabine metastatic pancreatic cancer. Prior to joining Merrimack, Al-Wakeel was a director on the healthcare investment banking team at Credit Suisse.